Perrigo bats away raised Mylan bid
April 30, 2015Sales and Marketing Mylan, Perrigo, Teva, Vigodman, merger
Perrigo has rejected an updated $34.1 billion takeover bid from Mylan, whilst Teva has also written an open letter in …
NHS ‘close to breaking point’
April 30, 2015Medical Communications, Sales and Marketing BMJ, Godlee, Kings Fund, NHS, king's fund
England’s NHS is ‘stretched close to breaking point’ and the next five years are likely to be the most challenging …
FDA waves through generic BMS antipsychotic
April 30, 2015Manufacturing and Production, Sales and Marketing Alembic, BMS, FDA, Hetero and Torrent Pharmaceuticals, Teva
The FDA has approved four generic versions of Bristol-Myers Squibb’s top selling Abilify, an atypical antipsychotic drug approved to treat …
Recipharm appoints general manager for Italian unit
April 30, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Giorgio Bruno, Recipharm
Contract development and manufacturing organisation Recipharm has confirmed that Dr Giorgio Bruno has been appointed general manager of Recipharm Italia. In …
Pharma accused of hiding behind regulation and undermining NICE
April 29, 2015Medical Communications, Sales and Marketing NHS, NICE, Royal Society of Medicine, UK, brett wells, health, pharma
University of York health economists have argued that pharma regulation is not evidence-based, lacks accountability and undermines NICE. Writing in …
Pfizer posts second consecutive quarterly income decline
April 29, 2015Sales and Marketing 2015, Pfizer, Q1, first quarter
Pfizer made 4% less revenue in the first quarter of 2015 compared with the same period last year, the company’s …
Merck sales fall in Q1 despite new product lifts
April 29, 2015Sales and Marketing Merck, Q1, Remicade
Merck’s sales were down in the first quarter of 2015 thanks to its consumer care divestment and increasing competition for …
GSK shingles vaccine performs
April 29, 2015Research and Development, Sales and Marketing GSK, GlaxoSmithKline, HZ/su, Merck, zostovax
GlaxoSmithKline’s HZ/su vaccine candidate for the prevention of shingles has demonstrated promising benefits across all age groups in a late-stage …
Conference round-up: companies go big on hepatitis C at EASL
April 29, 2015Sales and Marketing Bristol-Myers Squibb, EASL, Merck, daclatasvir, daklinza
Big pharma names posted favourable results for hepatitis C treatments as they jostled for position as market leaders at the …
RSA hires two consultants in Germany
April 29, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andreas Reimer, Ji Kwon, rsa
Executive search and interims firm RSA has appointed two consultants to its teams in the DACH region. Andreas Reimer (pictured) …
Helping Nepal – SHL to Match Staff Donations
April 29, 2015Sales and Marketing helping nepal, shl group, world vision
In immediate response to the devastating earthquake that left Nepal in ruins on April 25th, SHL quickly reached out to …
BMS lifted by new products
April 28, 2015Sales and Marketing BMS, NICE, Q1, eams, immuno-oncology and hepatitis C
New drugs have helped Bristol-Myers Squibb see a slight increase in sales for the first quarter of 2015. Total revenues …
Celgene splashes out on cancer R&D firm
April 28, 2015Research and Development, Sales and Marketing
Oncology specialists Celgene have made a $485 million outlay to buy Quanticel Pharmaceuticals, to increase its effort and investment in …
UK ‘has ten years to become global biotech leader’
April 28, 2015Manufacturing and Production, Research and Development, Sales and Marketing
The UK should be home to ‘the third global cluster’ for biotech in the next 10 years, according to a …
M&A drama continues as Mylan rejects Teva
April 28, 2015Sales and Marketing M&A, MA, Mylan, Perrigo, Teva, bids, generics, takeovers
Mylan has firmly rejected Teva’s acquisition bid, even though its own bid for Irish firm Perrigo has also been turned …
Researchers hit out at ‘alarming’ increase in MS drug costs
April 27, 2015Manufacturing and Production, Research and Development, Sales and Marketing
Researchers have hit out at the ‘alarming’ rise in the costs of disease-modifying treatments for multiple sclerosis, in a new …
Big-name generics among new CHMP recommendations
April 27, 2015Sales and Marketing CHMP, EMA, European Medicines Agency, Lyrica, pregabalin
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended 11 new medicines for approval, among them several …
The Pharmafocus debate: Is the price of new hepatitis C treatments fair?
April 27, 2015Research and Development, Sales and Marketing Doctors of the World, Drug pricing, EFPIA, Gilead, MSF, drug cost, hepatitis C, patents, sofosbuvir, sovaldi
YES – says Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), who argues that …
EMA approves BMS’ Opdivo for advanced skin cancer
April 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer
Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …
AstraZeneca looks to oncology match-ups to boost sales
April 24, 2015Sales and Marketing AstraZeneca, Brilinta, Celgene, Innate, Juno, farxiga, ticagrelor
AstraZeneca posted a 1% increase in revenue in its first-quarter 2015 financials – and is investing the money to back …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
